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Abstract
Background: Chronic obstructive pulmonary disease (COPD), is a very common disease of respiratory system. An increasing number of clinical
trials on Yupingfeng formula in the management of stable COPD have been performed. However, the evidence base for it remains unknown. This
review aims at assessing the efficacy, and safety of modified Yupingfeng formula in the treatment of stable COPD through a systematic review of
all available randomized controlled trials.
Materials and Methods: Literature retrieval was conducted using four English databases (CENTRAL, PubMed, EMBASE, and ISI Web of
Science), and four Chinese databases (CBM, CNKI, VIP, and WANFANG), from respective inception to January 2013, and supplemented with a
manual search. Review authors independently extracted the trial data, and assessed the quality of each trial. Methodological quality was assessed
by Cochrane risk of bias and Jadad’s scale. The following outcomes were evaluated: (1) lung function; (2) 6-minute walk distance (6MWD); (3)
effective rate; (4) serum levels of IgA, IgG and IgE; and (5) adverse events. Data were analyzed using STATA 12.0 software.
Results: A total of nine studies involving 660, stable COPD patients were identified. Patients from all studies included in this review were
randomized to receive Yupingfeng formula combined with Western medications in comparison with Western medications. In general, the
methodological quality of the included trials was poor. The results of this systematic review indicates that, compared with Western medications
alone, the use of Yupingfeng formula, if combined with Western medications could significantly improve FEV1 (WMD = 0.30L; 95%CI: 0.19,
0.42), FEV1/FVC ratio (SMD = 0.69; 95%CI: 0.48, 0.91), 6MWD (WMD = 31.73m; 95% CI: 19.29, 44.17), and effective rate (RR = 1.24; 95%
CI: 1.10, 1.41), and increase the serum levels of IgA (WMD = 0.25; 95%CI: 0.16, 0.34) and IgG (WMD = 1.10; 95%CI: 0.53, 1.68), but no
difference was found in the serum IgE levels (WMD = 0.47; 95%CI: －0.32, 1.27) between the two groups. No serious adverse events were
reported.
Conclusions: Within the limitations of this systematic review, we may conclude that compared with Western medications alone, Yupingfeng
formula, when combined with Western medications can provide more benefits for patients with stable COPD, without any serious adverse
reactions being identified. However, these benefits need to be further confirmed through high-quality prospective placebo-controlled trials that
should be strictly conducted in accordance with methodological principles and procedures.
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Introduction
Chronic obstructive pulmonary disease (COPD), is a common preventable disease characterized by persistent airflow limitation that is
usually progressive. Although it can be properly managed, [COPD], is said to be one of the leading cause with high morbidity and mortality rates
globally, resulting into an economic, and social burden that is both substantial and increasing. It ranked sixth as a major cause of death in 1990,
and it is estimated that COPD will become the fourth leading cause of death globally by 2030. The prevalence and associated socio-economic
burdens of COPD are projected to increase in the coming decades (Gold members, 2013).
Conventional therapy for stable COPD is aimed at relieving symptoms, reducing long-term lung function decline, preventing exacerbations,
and improving health status and exercise tolerance. The management steps of COPD includes smoking cessation, oxygen therapy, physical
activity, pulmonary rehabilitation, nutritional supplementation, vaccinations, and the use of inhaled corticosteroids, long-acting bronchodilators,
or combination of corticosteroid and bronchodilator therapy if necessary (Qaseem et al., 2011). However, COPD is a progressive disease leading
to a decrease in lung function over time with the best available care. Till date, none of the existing Western medications for COPD has been
conclusively shown to modify the long-term decline in lung function (Gold members, 2013). Unsatisfactory treatment response from conventional
Western drugs contributes to the increasing popularity of Traditional Chinese Medicine (TCM).
TCM has its potential advantages different from modern medicines, and is recognized as an attractive alternative to conventional Western
medicine. There is a long history in the use of TCM in treating respiratory diseases, particularly in China, Japan, and other Asian countries
(Sorkness et al., 2009). According to the TCM theory, COPD should be classified in the category of syndrome characterized by dyspnea and
cough. From the standpoint of TCM patients, COPD usually manifest with Qi-deficiency syndrome (Fu et al., 2007). In TCM, Qi is one of the
most important substances in the body, and it spreads over the whole body via its dispersing and descending functions. When the Qi is too weak
to control the pores and protect the body, the patient is more susceptible to catching a cold (Yang et al., 2010; Dowie et al., 2009), which
commonly leads to acute exacerbations of COPD. Therefore, the treatment principle of COPD should focus on nourishing Qi. Previous clinical
studies have demonstrated ginseng or combined with other herbs can improve the lung function of patients with COPD (An et al., 2011).
Yupingfeng formula (Gyokuheifu-san in Japanese, Jade Windscreen Powder in English), originally recorded in the book Danxi Xinfa, is a
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classical TCM formula consisting of three herbal medicines, i.e. Huang Qi (Astragalus membranaceus); Bai Zhu (Rhizoma atractylodis
macrocephalae); and Fang Feng (Radix saposhnikoviae). Huang Qi is a powerful medicine for strengthening Qi of spleen and lung to activate
body energy as well as to protect the body form external pathogens. Bai Zhu strengthens spleen, which is the source of Qi. Fang Feng can benefit
the defensive Qi, and consolidate the exterior. By combining these three herbal medicines, Yupingfeng formula has the potential to invigorate Qi
and consolidate the superficial resistance, which may increase a patient’s ability to protect himself from invasion by external pathogenic influence
(Makino et al., 2004). It is frequently used for treating spontaneous sweating, aversion to wind, weakness and a susceptibility to catching colds.
Moreover, it has been widely prescribed for hundreds of years to prevent or treat respiratory tract diseases, such as perennial allergic rhinitis,
respiratory infections, bronchial asthma, and COPD when present as Qi-deficiency syndrome (Fang et al., 2005). Increasing efforts have been
directed towards seeking for relevant scientific evidence, and an increasing number of clinical trials on Yupingfeng formula in the management of
COPD have been performed, but the findings have not yet been systematically summarized.
The purpose of the current systematic review was to assess the efficacy and safety of modified Yupingfeng formula in the treatment of
COPD through a systematic collection of evidence from randomized controlled trials (RCTs). It was expected that, this systematic review could
provide more evidence-based information for real-world clinical practice.
Methods
Criteria for considering studies for this review
Types of studies
Only [RCTs], were eligible for this review, irrespective of blinding. Quasi-randomized and nonrandomized controlled trials were not
considered.
Types of participants
We reviewed studies of adults with COPD defined as progressive chronic air-flow limitation evident by spirometry with a
post-bronchodilator FEV1/FVC ratio < 70%, regardless of smoking history. Patients were in a clinically stable state at the start of the study,
without recent exacerbation, hospitalization or, any need for antibiotics nor systemic corticosteroids. Patients did not have any clinical features of
asthma.
Types of interventions
A comparative study between Yupingfeng formulas or, when combined with Western medications, and placebo; no treatment or, same
Western medications as controls were included. In clinical practice of TCM, it is common to modify original formula by adding or substituting
herbs in accordance with a patient’s syndrome to enhance the efficacy of the original formula. Thus, any form of administration of Yupingfeng
formula or its modified prescription such as decoction, capsule, tablet, pill, and powder was acceptable for inclusion in the review. Papers were
excluded when Chinese herbs or other TCM therapies were used in the control group.
Types of outcome measures
The primary outcome measure was lung function.
Secondary outcomes included: (1) exercise capacity (6-minute walk distance, 6MWD); (2) effective rate defined as the symptoms scores
reduced rate (cough, cough-up phlegm, dyspnea, wheezing or other lung symptoms) ≥ 30% according to the Chinese criteria "Guiding Principle
of Clinical Research on New Drugs of TCM" (Zhen et al., 2002; Chen et al., 2010; Bian et al., 2008); (3) serum levels of IgA, IgG and IgE; and (4)
adverse events.
Search methods for identification of studies
The retrieval of trials was performed in the Cochrane Central Register of Controlled Trials (CENTRAL), Pub Med, EMBASE, ISI Web of
Science, Chinese Biomedical Database (CBM); Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific and Technological
Periodical Database (VIP), and WANFANG Database. All databases were searched from their respective inception dates, to January 2013.
Searches were conducted to identify all relevant studies regardless of language or publication status. The search strategy was constructed by using
a combination of subject headings and text words relating to the use of Yupingfeng formula in the treatment of patients with stable COPD. The
search terms used in PubMed were [(((((Yupingfeng[Title/Abstract]) OR Yu Ping Feng[Title/Abstract]) OR Gyokuheifu [Title/Abstract]) OR Jade
Windscreen[Title/Abstract]) OR "yupingfeng" [Supplementary Concept]) AND ("Pulmonary Disease, Chronic Obstructive"[Mesh] OR "COPD,
Severe Early-Onset" [Supplementary Concept]) OR chronic obstructive pulmonary disease[Title/Abstract]) OR chronic obstructive lung
disease[Title/Abstract]) OR chronic obstructive airway disease[Title/Abstract]) OR chronic airflow obstruction[Title/Abstract]) OR obstructive
airway disease [Title/Abstract]) OR COPD[Title/Abstract]) OR COAD[Title/Abstract]) OR chronic bronchitis[Title/Abstract]) OR
emphysema[Title/Abstract]) AND (("Randomized Controlled Trial"[Publication Type] OR "Randomized Controlled Trials as Topic"[Mesh]) OR
random*[Title/Abstract])]. Various combinations of the terms were used, depending on the database searched. We also searched on-line web sites
including journal websites and databases of ongoing trials.
In addition, a manual search of ten leading TCM journals was performed to identify other potentially relevant studies. Meanwhile, we also
searched the reference lists of review articles and identified RCTs for any possible titles matching the inclusion criteria. Furthermore, we
contacted experts in this field, and relevant pharmaceutical companies for other unpublished studies.
Selection of studies
Two review authors (Yunqing Zhong and Xiufeng Wang), independently selected trials for inclusion by scanning the titles, abstract sections,
and keywords of each study retrieved and the full-text articles if necessary. Agreement between review authors for inclusion of studies was
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recorded.
Data extraction and management
To avoid bias in the data extraction process, the review authors (Bing Mao and Wei Zhou) independently extracted data using a piloted data
extraction form and compared the results. They were not blinded to study authors, institutions, or journals of publication. Details of participants,
severity of COPD, COPD duration, study design, interventions, outcome measures and adverse events of each study were extracted. Any lack of
information was supplemented by correspondence with the original principal investigators. Each entry was double-checked by both reviewers. All
review authors participated in resolving discrepancies until a consensus was reached.
Quality assessment
Risk of bias was independently assessed by two review authors (Jie Min and Hongli Jiang), according to the criteria specified in the
Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (Higgins et al., 2013) across six domains, i.e. sequence generation, allocation
concealment, blinding, incomplete outcome data, selective outcome reporting and other potential sources of bias. Each domain was classified as
having either a high, low, or unclear risk of bias. We also used the Jadad scoring system for quality assessment, which evaluates a study in terms
of the description of randomization, blinding, and dropouts. The Jadad scale is a 5-point scale for assessing the quality of randomized trials in
which three points or more indicate superior quality (Jadad et al., 1996). Discrepancies were resolved by consensus. If required, a third party
(Bing Mao) would be consulted. To avoid selection bias, no study was rejected because of these quality criteria.
Data synthesis
All calculations were conducted using STATA software (STATA version 12.0, StataCorps, College Station, Texas, USA). We performed the
meta-analysis by pooling homogeneous studies. For dichotomous data, we presented results as relative risk (RR), with 95% confidence interval
(CI). For continuous data, we calculated weighted mean difference (WMD) if outcomes were measured in a same way among trials or
standardized mean difference (SMD) if outcomes were measured by different methods among trials. Heterogeneity between the trials was
analyzed by Cochrane’s Q test, and potential reasons for heterogeneity were also explored. If the analysis showed low heterogeneity (P ≥ 0.10 and 
I2 ≤ 50%), data were synthesized using a fixed-effect model. Otherwise, a random-effects model was applied. Publication bias was assessed by 
Egger’s and Begg’s statistical tests and funnel plot if the meta-analysis included more than 10 trials (Sedgwick P., 2013). A two-tailed P value less
than 0.05 was considered statistically significant.
Sensitivity analysis
We used STATA’s METANINF command to investigate whether the exclusion of any one study would significantly change the pooled
estimate, that is, whether the pooled point estimate with one study excluded would lie outside the 95% CI of the pooled estimate with all studies
included. If the sensitivity analysis was close to the results of the complete study analysis, this strengthened the level of confidence.
Results
Description of studies
Figure 1: show the paper selection process, and exclusion reasons. A total of 76, potentially eligible citations were identified in the initial
search, of which 45, were excluded because those were not relevant to the topic. Based on title and abstract, other 13, articles were further
excluded for the following reasons: 2, review articles, and 11, animal studies. Two studies that were pre-post comparisons with no control group
were also excluded. Of the remaining 16, articles, two additional trials which enrolled patients with acute exacerbations of COPD were further
excluded. After careful examination of the retrieved articles, 4 were also excluded because other Chinese herbs were used as controls. One trial
(Li et al., 2010), was presented in two papers, therefore this was considered as one study. Finally, a total of 9 RCTs (Huang et al., 2005; Zhao et
al., 2009; Li et al., 2010; Xu J., 2010; Xu X.H., 2010; Zhang et al., 2011; Liao et al., 2011; Liu et al., 2012; Wang et al., 2012) that satisfied the
inclusion criteria were included. All of the included studies compared Yupingfeng formula combined with conventional Western medications
(therapy A) with the same conventional Western medications alone (therapy B).
Figure.1: Flow diagram showing the stages of the identification of studies for the meta-analysis.
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Characteristics of included trials
The main characteristics of the included trials are listed in Tables 1 and 2. All of the identified studies involving a total of 660, stable COPD
patients were conducted in China, and all articles were written in Chinese language. None of these was designed as a multicenter study. All trials
were published in scientific journals, no unpublished dissertations or conference papers were included. All nine trials were parallel-design,
randomized controlled trials. The publication years of these studies ranged from 2005, to 2012. The number of subjects included in each study
ranged from 40-100. Eight studies (Huang et al., 2005; Zhao et al., 2009; Li et al., 2010; Xu J., 2010; Zhang et al., 2011; Liao et al., 2011; Liu et
al., 2012; Wang et al., 2012), enrolled both men and women, and the other study (Xu, X.H., 2010) conducted exclusively in men. Four studies
(Zhao et al., 2009; Zhang et al., 2011; Liao et al., 2011; Liu et al., 2012) did not specify the severity classification of airflow limitation in COPD
subjects. Two trials (Xu, X.H., 2010; Zhang et al., 2011) reported withdrawals, and dropouts. One (Xu, X.H., 2010) did not provide reasons, while
the other (Zhang et al., 2011), explained by the following reasons: 2 patients in therapy A group suffered from COPD exacerbations, and 5 could
not tolerate TCM; 4 patients in therapy B group withdrew due to COPD exacerbations, and 1 experienced a cerebrovascular accident.
Methodological quality
Assessment of risk of bias
All the included studies claimed "randomization", but only three studies (Li et al., 2010; Xu X.H., 2010; Liao et al., 2011), clearly described
the method of randomization (a random number table). Thus, the information of sequence generation was adequate for three studies (Li et al.,
2010; Xu X.H., 2010; Liao et al., 2011) at low risk of bias (yes) and inadequate for 6 studies (Huang et al., 2005; Zhao et al., 2009; Xu J, 2010;
Zhang et al., 2011; Liu et al., 2012; Wang et al., 2012), with uncertain risk of bias (unclear). No trials described allocation concealment, and the
domain was judged as ‘unclear’ in all studies. Blinding procedures (single-blind) were mentioned in two studies (Huang et al., 2005; Liao et al.,
2011), but no trials provided information about the blinding of either participants or investigators after assignment to interventions. Two studies
(Xu X.H., 2010; Zhang et al., 2011), provided data on withdrawals, but only one (Zhang et al., 2011), described the reasons. No trials described
intention-to-treat analyses (ITT), or the method of assessing compliance. No studies mentioned a previous published protocol, but two studies
(Liao et al., 2011; Wang et al., 2012) included all expected outcomes. Thus, selective outcome reporting was at low risk of bias in 2 studies (Liao
et al., 2011; Wang et al., 2012) and at uncertain risk of bias in 7 studies (Huang et al., 2005; Zhao et al., 2009; Li et al., 2010; Xu J., 2010; Xu
X.H., 2010; Zhang et al., 2011; Liu et al., 2012). Assessment of other sources of bias included early stopping for benefit and baseline imbalance.
The baseline characteristics of the trial and control groups in the included trials were comparable. But none of the studies described any
pre-calculated sample size, and information on early stopping was insufficient. Overall, the domain was rated as "unclear" in all studies. Detailed
information is shown in Table 3.
Assessment of Jadad’s scale
Through reading the full text, all nine studies’ level of evidence was graded scores lower than three according to the Jadad quality score.
Four studies (Li et al., 2010; Xu X.H., 2010; Zhang et al., 2011; Liao et al., 2011) were rated with a score of two, and five studies (Huang et al.,
2005; Zhao et al., 2009; Xu J., 2010; Liu et al., 2012; Wang et al., 2012) with a score of 1. In general, the methodological quality of the included
trials was poor (Table 2).
Effects of interventions
FEV1
A total of six trials (Huang et al., 2005; Zhao et al., 2009; Li et al., 2010; Liao et al., 2011; Liu et al., 2012; Wang et al., 2012) involving 370,
stable COPD patients provided data on the FEV1. The random-effects model was used because of intertribal heterogeneity (variability in the
intervention effects across studies) of the results of trials (I2 = 51.4%, P = 0.067). A pooled analysis of the 6 trials showed that therapy A improved
the FEV1 to a greater extent than therapy B (WMD = 0.30L; 95%CI: 0.19, 0.42) (Figure 2).
FEV1/FVC ratio
This outcome was reported in five trials (Huang et al., 2005; Xu J., 2010; Liao et al., 2011; Liu et al., 2012; Wang et al., 2012) which
included 346 patients. A pooled analysis was conducted using the fixed-effect model (I2 = 0.0%, P = 0.602). Statistically significant differences
were noted between the two groups, and these results suggested that therapy A significantly improved the FEV1/FVC ratio compared with therapy
B (SMD = 0.69; 95%CI: 0.48, 0.91) (Figure 3).
6MWD
A pool analysis of 4 trials (Huang et al., 2005; Zhang et al., 2011; Liao et al., 2011; Wang et al., 2012) was performed using a fixed-effect
model (I2 = 0.0%, P = 0.401). Results indicated that 6MWD was significantly improved in therapy A group compared with therapy B group
(WMD = 31.73m; 95% CI: 19.29, 44.17) (Figure 4).
Effective rate (the symptoms scores reduced rate)
Seven trials (Zhao et al., 2009; Li et al., 2010; Xu J., 2010; Xu X.H., 2010; Liao et al., 2011; Liu et al., 2012; Wang et al., 2012) reported
data on the outcome measure of effective rate, which was defined according to the criteria outlined in the "Guiding Principle of Clinical Research
on New Drugs of Traditional Chinese Medicine" (Zhen et al., 2002). The random-effects model was used because of inter-tribal heterogeneity of
the results of trials (I2 = 57.5%, P = 0.028). Results revealed significant differences between the two groups (P = 0.001), which was in favor of
therapy A (RR = 1.24; 95% CI: 1.10, 1.41) (Figure 5).
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Serum levels of IgA, IgG and IgE
Three (Xu X.H., 2010; Liao et al., 2011; Wang et al., 2012), out of the nine studies that compared therapy A, with therapy B reported serum
IgA, IgG and IgE levels suitable for analysis. Further meta-analysis was conducted for the individual domains: IgA (WMD = 0.25; 95%CI: 0.16,
0.34); IgG (WMD = 1.10; 95%CI: 0.53, 1.68); and IgE (WMD = 0.47; 95%CI: －0.32, 1.27) (Fig. 6). The concentrations of serum IgA and IgG
in stable COPD patients receiving therapy A were significantly higher than those receiving therapy B, and patients receiving therapy A were more
likely to gain improvements in serum IgA, and IgG levels. But no difference was found in the serum IgE levels between the two groups, and there
was no evidence that therapy A significantly altered the levels of serum IgE compared with therapy B.
Adverse events
One study (Huang et al., 2005) stated that two patients receiving therapy A experienced dry mouth and mild abdominal distension, and 1
subject receiving therapy B complained of loss of appetite. But all of these symptoms gradually disappeared after proper medical treatment. The
remaining eight studies did not report any adverse events.
Publication bias
In general, if the number of studies is less than 10, a funnel plot is thought to be an unreliable method of investigating publication bias
(Sedgwick, 2013). Due to the insufficient number of included studies, a formal assessment of reporting bias by visual inspection of a funnel plot
was not possible.
Sensitivity analysis
As shown in Figure 2, the meta-analysis of FEV1 revealed a relatively high degree of heterogeneity across the studies. We used STATA’s
METANINF command to examine the influence of an individual study on the pooled estimate (WMD) by excluding each study in turn. For
example, rerunning the analysis without the study (Li et al., 2010) changed the WMD from 0.30 (95%CI: 0.19, 0.42) to 0.37 (95%CI: 0.32, 0.42),
thus the influence of this study on the estimated overall effect size was minor. The results were not materially changed, which suggested the
stability of the results of the meta-analysis (Figure 7).
Figure 2: Meta-analysis of FEV1 in randomized controlled trials comparing Yupingfeng formula plus Western medications with the same Western
medications alone in the treatment of stable COPD. FEV1: forced expiratory volume in 1 second.
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Figure 3: Meta-analysis of FEV1/FVC ratio in randomized controlled trials comparing Yupingfeng formula plus Western medications with the
same Western medications alone in the treatment of stable COPD. FVC: forced vital capacity.
Figure 4: Meta-analysis of 6MWD in randomized controlled trials comparing Yupingfeng formula plus Western medications with the same
Western medications alone in the treatment of stable COPD. 6MWD: 6 minute walk distance.
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Table 1: Patient characteristics of the included studies
First author,
reference, (year)
Location of
Hospital
Source of
patients
No. of
Participants
No. of
Male/Female
Age
(Mean ± SD or age
range, years)
Severity of COPD COPD Duration
(Mean ± SD or
range, years)
Huang et al.,
2005
Guangdong, China Outpatients T: 32
C: 31
T: 21/11
C: 23/8
T: 69.5±11.8
C: 68.8±10.6
T: II 17, III 15
C: II 18, III 13
T: 8.5±3.2
C: 8.3±3.5
Zhao et al., 2009 Guangdong, China Inpatients T: 45
C: 30
T&C: 50/25 T&C: 67.3±5.2 NS T&C: 3-12
Li et al.,
2010
Beijing, China Outpatients T: 29
C: 20
T: 19/10
C: 14/6
T: 62±8.61
C: 61.12±8.12
T: Moderate 20, Severe 9
C: Moderate 16, Severe 4
NS
Xu J,
2010
Zhejiang, China NS T:50
C:50
T&C: 71/29 T&C: 45-79 Mild 54, Moderate 36, Severe 10 T&C: 3-41
Xu XH,
2010
Jiangsu, China NS T:45*/44#
C: 45
T: 44/0
C: 45/0
T&C: 60.1±7.7 T&C: II-III T&C: 10.1±4.2
Zhang et al.,
2011
Fujian, China NS T: 50*/43#
C: 50*/45#
T: 36/7
C: 39/6
T: 56.20±7.12
C: 55.21±7.01
NS T: 16.02±8.96
C: 15.26±9.10
Liao et al.,
2011
Hubei, China NS T: 30
C: 33
T: 21/9
C: 23/10
T: 37-72
C: 39-70
NS T: 5-33
C: 5-30
Liu et al.,
2012
Henan, China NS T: 20
C: 20
T: 19/1
C: 18/2
T: 66±11
C: 64±9
NS T: 20±10
C: 18±9
Wang et al., 2012 Sichuan, China NS T: 40
C: 40
NS T&C: 55-80 T&C: II-IV NS
T: treatment; C: control; NS=not specified; *: number of subjects randomized; #: number of subjects analyzed; COPD: chronic obstructive pulmonary disease; SD: standard
deviation.
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Table 2 Other detailed characteristics of the included studies
First author,
reference, (year)
Study design Methods
of
random
process
Interventions
(Trial group)
Interventions
(Control group)
Duration/
Follow-up
Outcome
measures
Adverse events Similarity
at baseline
ITT Jadad
score
Huang et al.,
2005
Randomized
single-blind
controlled trial
Unclear ·Modified Yupingfeng
granule;
·CWM
CWM 3 months/6
months
FEV1,
FEV1/FVC,
6MWD
T: dry mouth and
mild abdominal
distension (2
cases)
C: loss of
appetite (1
case)
Similar No 1
Zhao et al., 2009 Randomized
controlled trial
Unclear ·Modified Yupingfeng
powder;
·CWM
CWM (continuous low-flow
oxygen therapy,
prescriptions for eliminating
phlegm, etc)
12weeks/1
year
Effective
rate, FEV1
NS Similar No 1
Li et al.,
2010
Randomized
controlled trial
Random
number
table
·Jiawei Yupingfeng powder;
·CWM
CWM (sustained-release
aminophylline tablets,
ambroxol hydrochloride
tablets, and inhaled
ipratropium bromide aerosol)
90 days/NS Effective
rate, FEV1
NS Similar No 2
Xu J,
2010
Randomized
controlled trial
Unclear ·Yupingfeng granule;
·CWM
CWM (prescriptions for
facilitating expectoration,
suppressing cough and
relieving dyspnea)
16 weeks/NS FEV1/FVC,
effective rate
None Similar No 1
Xu XH,
2010
Randomized
controlled trial
Random
number
table
·Yushenyupingfeng
decoction;
·CWM
CWM (smoking cessation,
respiratory muscle training,
etc)
3 months/NS Effective
rate, IgA,
IgG, IgM
None Similar No 2
Zhang et al.,
2011
Randomized
controlled trial
Unclear ·Modified Yupingfeng
powder;
·Seretide 50/500
Seretide 50/500 24weeks/NS 6MWD NS Similar No 2
Liao et al.,
2011
Randomized
single-blind
controlled trial
Random
number
table
·Yupingfeng powder;
·CWM
CWM (health education,
respiratory muscle training,
etc)
3 months/NS FEV1,
FEV1/FVC,
effective rate,
6MWD, IgA,
IgG, IgM
None Similar No 2
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Liu et al.,
2012
Randomized
controlled trial
Unclear ·Jiawei Yupingfeng powder;
·CWM
CWM (smoking cessation,
respiratory muscle training,
sustained-release
aminophylline tablets,
ambroxol hydrochloride
tablets, and inhaled
ipratropium bromide aerosol)
90 days/NS FEV1,
FEV1/FVC,
effective rate
NS Similar No 1
Wang et al., 2012 Randomized
controlled trial
Unclear ·Yupingfeng powder;
·CWM
CWM (health education,
respiratory muscle training,
facilitating expectoration,
suppressing cough and
relieving dyspnea)
6 months/1
year
FEV1,
FEV1/FVC,
effective rate,
6MWD, IgA,
IgG, IgM
None Similar No 1
NS=not specified; CWM, conventional Western medicine; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 6MWD, 6-min walk distance
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Table 3 Assessment of risk of bias in the included studies
Selection bias Performance bias Detection bias Attrition bias Reporting bias Other biasFirst author,
reference, (year)
Random
sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
addressed
Free of Selective
outcome reporting
Free of Other
sources of bias
Huang et al., 2005 Unclear Unclear Yes Yes Unclear Unclear Unclear
Zhao et al., 2009 Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Li et al.,
2010
Yes Unclear Unclear Unclear Unclear Unclear Unclear
Xu J,
2010
Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Xu XH,
2010
Yes Unclear Unclear Unclear No Unclear Unclear
Zhang et al., 2011 Unclear Unclear Unclear Unclear No Unclear Unclear
Liao et al.,
2011
Yes Unclear Yes Yes Unclear Yes Unclear
Liu et al.,
2012
Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Wang et al., 2012 Unclear Unclear Unclear Unclear Unclear Yes Unclear
Yes, low risk of bias; No, high risk of bias; Unclear, uncertain risk of bias.
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Figure 5: Meta-analysis of effective rate (the symptoms scores reduced rate) in randomized controlled trials comparing Yupingfeng
formula plus Western medications with the same Western medications alone in the treatment of stable COPD.
Figure 6: Meta-analysis of serum IgA, IgG and IgE levels in randomized controlled trials comparing Yupingfeng formula combined
with Western medications with the same Western medications alone in the treatment of stable COPD.
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Figure 7: Results of an influence analysis in which the meta-analysis of FEV1 is re-estimated omitting each study in turn. For
example, rerunning the analysis without the study (Li et al., 2010) changed the weighted mean difference (WMD) from 0.30
(95%CI: 0.19, 0.42) to 0.37 (95%CI: 0.32, 0.42). The results were not materially changed, which suggested the stability of the
results of the meta-analysis. The straight vertical lines at 0.30, 0.19 and 0.42 represent the WMD, upper and lower 95% CI of the
complete study analysis, respectively.
Discussion
Yupingfeng formula, a well-known traditional Chinese medicine, commonly used to treat the diseases of the respiratory
system. The aim of this study was to provide a comprehensive systematic review to assess the efficacy and safety of modified
Yupingfeng formula for patients with stable COPD. The results of review indicate that compared with Western medications alone,
the use of Yupingfeng formula combined with Western medications could significantly improve lung function, 6MWD, and
effective rate (the symptoms scores reduced rate), and increase the serum IgA and IgG levels, but no difference was found in the
serum IgE levels between the two groups. Our current results indicate that Yupingfeng formula could significantly enhance the
humoral immune function through the increase of serum levels of IgA and IgG. Based on the results of this review, conventional
Western drugs given in combination with orally administered Yupingfeng formula seem superior to conventional Western drugs
alone for patients with stable COPD. Also, as no significant adverse events were observed in the included studies, Yupingfeng
formula appears to be well tolerated, even when combined with conventional Western medicine.
These findings are consistent with previous data. Makino et al., (2005a) found that Yupingfeng formula could stimulate
immune responses when the antigen had already invaded the body, and that it might consolidate the resistance of nasal mucosa to
protect from ovalbumin (OVA) invasion. Another study by Makino et al., (2004) showed that Yupingfeng formula had preventive
and curative effects on allergic rhinitis induced with Japanese cedar pollens in guinea pig. Song et al., (2013) observed that
Yupingfeng powder exhibited anti-inflammatory and immunoregulatory effects in a rat model of chronic bronchitis, and
time-dependent relationships in vitro. Moreover, pharmacological studies have showed that Yupingfeng formula as a holistic
Kampo medicine might affect human homeostasis and constitution of human beings, and increase the immunological function of
the body (Makino T., 2005b; Hong et al., 2011). The above pharmacological properties of Yupingfeng formula can partially explain
the clinical benefits identified in this review.
It is noteworthy that this review has several limitations. Firstly, as the definition of COPD has been changing over the years
(Chhabra S.K., 2009), differences in definition of the disease may bias our search results. Although a comprehensive search strategy
was adopted, we still cannot guarantee that all eligible trials have been identified. And we were also unable to use formal methods
to determine if there was any publication bias as too few studies were available. The possibility that there are unpublished studies or
other published studies that were not indexed in the electronic databases we searched cannot be excluded, because negative or no
significant findings are less likely to be published (Dirnagl et al., 2010). Secondly, the reporting of trial methods and procedures
was unclear and insufficient. The majority of the 9 included studies suffered from methodological weaknesses based on the
assessment of the Cochrane risk of bias and the Jadad’s scale. The inadequacy of sequence generation, allocation concealment and
blinding, and dropouts account were the major sources of potential bias. Low-quality trials are more likely to overestimate efficacy.
Therefore, these results must be interpreted with caution. Thirdly, none of these studies was designed as a multicenter study. Most
of the trials were of small sample size trials, and no studies estimated the sample size, which is essential for ensuring adequate
sample size and statistical power to detecting clinical significant difference between interventions (Eng J., 2003; Scales et al., 2005).
Fourthly, for the purpose of evaluating effects of therapies, the test intervention should be compared with placebo (Shah K.N.,
2009). However, no placebo-controlled trial has studied the efficacy and safety of Yupingfeng formula for stable COPD. Finally,
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although the safety profile of Yupingfeng formula has been demonstrated in this systematic review, we still cannot be assured of its
safety because the small sample sizes might have limited power to detect rare adverse events.
Although the results of this review may be limited by the low quality of the included trials, the findings are promising, and
further investigation into the efficacy and safety of Yupingfeng formula is worthy of merit. The methodological quality of clinical
trials on Yupingfeng formula in the treatment of stable COPD needs to be further improved in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) statement, and the publication of protocols should be encouraged (Schulz et al., 2010;
Gagnier et al., 2006). In particular, large-scale, transnational cooperative, rigorously designed, multicenter, randomized,
placebo-controlled, double-blind trials with explicit clinical and diagnostic criteria, sufficient duration of follow-up and description
of all relevant clinical outcome measures are still warranted.
Conclusions
Within the limitations of this systematic review, we may conclude that compared with Western medications alone, combined
Yupingfeng formula and Western medications can provide more benefits for patients with stable COPD, without any serious adverse
reactions being identified. There is encouraging evidence suggesting that Yupingfeng formula may be a safe and effective herbal
treatment option for patients with stable COPD. However, these benefits need to be further confirmed through high-quality
prospective trials that should be strictly conducted in accordance with methodological principles and procedures.
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